Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Expands By 66.9%

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 83,600 shares, an increase of 66.9% from the November 30th total of 50,100 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average trading volume of 55,200 shares, the short-interest ratio is presently 1.5 days.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH increased their price target on Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Marker Therapeutics Trading Up 3.6 %

MRKR traded up $0.12 during trading hours on Friday, hitting $3.49. The company’s stock had a trading volume of 78,461 shares, compared to its average volume of 31,547. Marker Therapeutics has a 12 month low of $2.44 and a 12 month high of $6.16. The business’s 50-day moving average price is $3.72 and its 200-day moving average price is $3.83.

Insider Transactions at Marker Therapeutics

In related news, major shareholder Enterprise Associates 16 New bought 554,250 shares of the stock in a transaction dated Monday, December 23rd. The shares were purchased at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the acquisition, the insider now owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. This represents a 51.73 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steve Elms bought 11,085 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average cost of $3.20 per share, with a total value of $35,472.00. Following the completion of the purchase, the director now directly owns 325,370 shares of the company’s stock, valued at $1,041,184. This represents a 3.53 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 17.35% of the company’s stock.

Institutional Trading of Marker Therapeutics

A hedge fund recently bought a new stake in Marker Therapeutics stock. Invst LLC acquired a new position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned about 0.22% of Marker Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.